View ValuationHualan Biological Engineering 将来の成長Future 基準チェック /16Hualan Biological Engineering利益と収益がそれぞれ年間18.1%と7.8%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に9.7% 16.5%なると予測されています。主要情報18.1%収益成長率16.53%EPS成長率Biotechs 収益成長29.7%収益成長率7.8%将来の株主資本利益率9.66%アナリストカバレッジGood最終更新日07 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jun 30Hualan Biological Engineering Inc. to Report First Half, 2026 Results on Aug 29, 2026Hualan Biological Engineering Inc. announced that they will report first half, 2026 results on Aug 29, 2026Declared Dividend • Jun 11Dividend of CN¥0.50 announcedShareholders will receive a dividend of CN¥0.50. Ex-date: 15th June 2026 Payment date: 15th June 2026 Dividend yield will be 7.6%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is not covered by earnings (213% earnings payout ratio) nor is it covered by cash flows (270% cash payout ratio). The dividend has increased by an average of 23% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 137% to bring the payout ratio under control. EPS is expected to grow by 65% over the next 3 years, which means the dividend may need to be reduced to reach a sustainable payout ratio.お知らせ • Jun 10Hualan Biological Engineering Inc. Announces 2025 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 15 June 2026Hualan Biological Engineering Inc. announced 2025 final profit distribution plan to be implemented (A shares) of CNY 5.00000000 per 10 shares(tax included). Record date: 12 June 2026, Ex-date: 15 June 2026, Payment date: 15 June 2026.Board Change • May 20Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 5 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Zhiqian Zhang was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Mar 31Hualan Biological Engineering Inc. to Report Q1, 2026 Results on Apr 27, 2026Hualan Biological Engineering Inc. announced that they will report Q1, 2026 results on Apr 27, 2026お知らせ • Mar 28Hualan Biological Engineering Inc., Annual General Meeting, Apr 20, 2026Hualan Biological Engineering Inc., Annual General Meeting, Apr 20, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinxiang, Henan Chinaお知らせ • Dec 31Hualan Biological Engineering Inc. to Report Fiscal Year 2025 Results on Mar 28, 2026Hualan Biological Engineering Inc. announced that they will report fiscal year 2025 results on Mar 28, 2026お知らせ • Sep 30Hualan Biological Engineering Inc. to Report Q3, 2025 Results on Oct 30, 2025Hualan Biological Engineering Inc. announced that they will report Q3, 2025 results on Oct 30, 2025お知らせ • Sep 24Hualan Biological Engineering Inc. Approves Interim Dividend for 2025Hualan Biological Engineering Inc. held its 2nd Extraordinary General Meeting of 2025 on 22 September 2025, approved interim Cash dividend/10 shares (tax included): CNY5.00000000 for 2025.お知らせ • Aug 29Hualan Biological Engineering Inc. Proposes Interim Cash Dividend for 2025Hualan Biological Engineering Inc. at its EGM to be held on September 22, 2025, proposed the detailed profit distribution plan are as follows: Cash dividend/10 shares (tax included): CNY5.00000000.お知らせ • Jul 02Hualan Biological Engineering Inc. to Report First Half, 2025 Results on Aug 29, 2025Hualan Biological Engineering Inc. announced that they will report first half, 2025 results on Aug 29, 2025お知らせ • Apr 01Hualan Biological Engineering Inc. Proposes Final Cash Dividend for the Year 2024Hualan Biological Engineering Inc. announced on 31 March 2025 the profit distribution proposal for the year 2024 as final cash dividend/10 shares (tax included) of CNY 2.00000000.お知らせ • Mar 31Hualan Biological Engineering Inc. to Report Q1, 2025 Results on Apr 28, 2025Hualan Biological Engineering Inc. announced that they will report Q1, 2025 results on Apr 28, 2025お知らせ • Mar 29Hualan Biological Engineering Inc., Annual General Meeting, Apr 25, 2025Hualan Biological Engineering Inc., Annual General Meeting, Apr 25, 2025, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinxiang, Henan Chinaお知らせ • Dec 31Hualan Biological Engineering Inc. to Report Fiscal Year 2024 Results on Mar 29, 2025Hualan Biological Engineering Inc. announced that they will report fiscal year 2024 results on Mar 29, 2025Reported Earnings • Oct 30Third quarter 2024 earnings released: EPS: CN¥0.27 (vs CN¥0.30 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.27 (down from CN¥0.30 in 3Q 2023). Revenue: CN¥1.84b (down 21% from 3Q 2023). Net income: CN¥483.5m (down 11% from 3Q 2023). Profit margin: 26% (up from 23% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings.お知らせ • Sep 30Hualan Biological Engineering Inc. to Report Q3, 2024 Results on Oct 31, 2024Hualan Biological Engineering Inc. announced that they will report Q3, 2024 results on Oct 31, 2024Valuation Update With 7 Day Price Move • Sep 27Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CN¥16.41, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 21x in the Biotechs industry in China. Total loss to shareholders of 39% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥27.89 per share.Reported Earnings • Aug 30Second quarter 2024 earnings released: EPS: CN¥0.098 (vs CN¥0.096 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.098 (up from CN¥0.096 in 2Q 2023). Revenue: CN¥865.4m (up 23% from 2Q 2023). Net income: CN¥178.4m (up 2.0% from 2Q 2023). Profit margin: 21% (down from 25% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings.お知らせ • Jun 29Hualan Biological Engineering Inc. to Report First Half, 2024 Results on Aug 30, 2024Hualan Biological Engineering Inc. announced that they will report first half, 2024 results on Aug 30, 2024Declared Dividend • Jun 08Dividend of CN¥0.30 announcedDividend of CN¥0.30 is the same as last year. Ex-date: 14th June 2024 Payment date: 14th June 2024 Dividend yield will be 1.7%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by earnings (39% earnings payout ratio) but not covered by cash flows (159% cash payout ratio). The dividend has increased by an average of 25% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 62% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Jun 08Hualan Biological Engineering Inc. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 14 June 2024Hualan Biological Engineering Inc. announced final profit distribution plan to be implemented on A shares as cash dividend per ten shares (tax included) of CNY 3.00000000 for the year 2023, payable on 14 June 2024. Record date: 13 June 2024. Ex-date: 14 June 2024.Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.19 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.14 (down from CN¥0.19 in 1Q 2023). Revenue: CN¥787.3m (down 11% from 1Q 2023). Net income: CN¥261.8m (down 26% from 1Q 2023). Profit margin: 33% (down from 40% in 1Q 2023). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.Reported Earnings • Apr 01Full year 2023 earnings released: EPS: CN¥0.81 (vs CN¥0.59 in FY 2022)Full year 2023 results: EPS: CN¥0.81 (up from CN¥0.59 in FY 2022). Revenue: CN¥5.34b (up 18% from FY 2022). Net income: CN¥1.48b (up 38% from FY 2022). Profit margin: 28% (up from 24% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.お知らせ • Mar 30Hualan Biological Engineering Inc. to Report Q1, 2024 Results on Apr 26, 2024Hualan Biological Engineering Inc. announced that they will report Q1, 2024 results on Apr 26, 2024お知らせ • Dec 30Hualan Biological Engineering Inc. to Report Fiscal Year 2023 Results on Mar 30, 2024Hualan Biological Engineering Inc. announced that they will report fiscal year 2023 results on Mar 30, 2024Reported Earnings • Nov 01Third quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.17 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.30 (up from CN¥0.17 in 3Q 2022). Revenue: CN¥2.33b (up 86% from 3Q 2022). Net income: CN¥540.6m (up 70% from 3Q 2022). Profit margin: 23% (down from 25% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings.Reported Earnings • Aug 24Second quarter 2023 earnings released: EPS: CN¥0.096 (vs CN¥0.19 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.096 (down from CN¥0.19 in 2Q 2022). Revenue: CN¥704.6m (down 59% from 2Q 2022). Net income: CN¥175.0m (down 50% from 2Q 2022). Profit margin: 25% (up from 20% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 29% per year, which means it is performing significantly worse than earnings.お知らせ • Jun 08Hualan Biological Engineering Inc. Announces Final Dividend on Share A for 2022, Payable on June 14, 2023Hualan Biological Engineering Inc. announced final Cash dividend/10 shares (tax included): CNY 3.00000000 on share A for 2022. Record date: 13 June 2023, Ex-date: 14 June 2023, Payment date: 14 June 2023.Reported Earnings • Mar 30Full year 2022 earnings released: EPS: CN¥0.59 (vs CN¥0.71 in FY 2021)Full year 2022 results: EPS: CN¥0.59 (down from CN¥0.71 in FY 2021). Revenue: CN¥4.52b (up 1.8% from FY 2021). Net income: CN¥1.08b (down 17% from FY 2021). Profit margin: 24% (down from 29% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Yunlong Wang was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 31Third quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.33 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.17 (down from CN¥0.33 in 3Q 2021). Revenue: CN¥1.25b (down 40% from 3Q 2021). Net income: CN¥317.6m (down 47% from 3Q 2021). Profit margin: 25% (down from 29% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 24Second quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.11 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.19 (up from CN¥0.11 in 2Q 2021). Revenue: CN¥1.71b (up 157% from 2Q 2021). Net income: CN¥349.1m (up 71% from 2Q 2021). Profit margin: 20% (down from 31% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to stay flat compared to a 34% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Jun 21Investor sentiment improved over the past weekAfter last week's 19% share price gain to CN¥22.86, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 30x in the Biotechs industry in China. Total returns to shareholders of 4.1% over the past three years.Board Change • May 25Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Yunlong Wang was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 01Full year 2021 earnings released: EPS: CN¥0.71 (vs CN¥0.89 in FY 2020)Full year 2021 results: EPS: CN¥0.71 (down from CN¥0.89 in FY 2020). Revenue: CN¥4.44b (down 12% from FY 2020). Net income: CN¥1.30b (down 20% from FY 2020). Profit margin: 29% (down from 32% in FY 2020). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 9.4%, compared to a 51% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Sep 08Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to CN¥30.13, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 36x in the Biotechs industry in China. Total returns to shareholders of 71% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥17.49 per share.Reported Earnings • Aug 30Second quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.14 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥665.2m (down 6.2% from 2Q 2020). Net income: CN¥204.5m (down 23% from 2Q 2020). Profit margin: 31% (down from 37% in 2Q 2020). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 17% per year whereas the company’s share price has increased by 21% per year.Reported Earnings • May 02First quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.14 in 1Q 2020)The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: CN¥623.4m (down 8.0% from 1Q 2020). Net income: CN¥252.8m (up 2.2% from 1Q 2020). Profit margin: 41% (up from 37% in 1Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Mar 31Full year 2020 earnings released: EPS CN¥0.89 (vs CN¥0.71 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: CN¥5.02b (up 36% from FY 2019). Net income: CN¥1.61b (up 26% from FY 2019). Profit margin: 32% (down from 35% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Mar 11Full year 2020 earnings released: EPS CN¥0.88 (vs CN¥0.70 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: CN¥5.02b (up 36% from FY 2019). Net income: CN¥1.60b (up 25% from FY 2019). Profit margin: 32% (down from 35% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.Analyst Estimate Surprise Post Earnings • Mar 11Revenue beats expectationsRevenue exceeded analyst estimates by 6.3%. Over the next year, revenue is forecast to grow 9.6%, compared to a 61% growth forecast for the Biotechs industry in China.Valuation Update With 7 Day Price Move • Feb 11Investor sentiment improved over the past weekAfter last week's 17% share price gain to CN¥53.98, the stock is trading at a trailing P/E ratio of 76.7x, up from the previous P/E ratio of 65.5x. This compares to an average P/E of 70x in the Biotechs industry in China. Total returns to shareholders over the past three years are 323%.Is New 90 Day High Low • Feb 11New 90-day high: CN¥53.98The company is up 21% from its price of CN¥44.63 on 13 November 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥45.10 per share.Valuation Update With 7 Day Price Move • Jan 12Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥52.97, the stock is trading at a trailing P/E ratio of 75.3x, up from the previous P/E ratio of 64.9x. This compares to an average P/E of 64x in the Biotechs industry in China. Total returns to shareholders over the past three years are 284%.Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improved over the past weekAfter last week's 19% share price gain to CN¥50.39, the stock is trading at a trailing P/E ratio of 71.6x, up from the previous P/E ratio of 60x. This compares to an average P/E of 65x in the Biotechs industry in China. Total returns to shareholders over the past three years are 261%.Is New 90 Day High Low • Nov 03New 90-day low: CN¥46.08The company is down 34% from its price of CN¥70.17 on 05 August 2020. The Chinese market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥23.11 per share.Reported Earnings • Nov 01Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥1.28b, down 4.4% from the prior year. Total revenue was CN¥4.13b over the last 12 months, up 8.3% from the prior year.Analyst Estimate Surprise Post Earnings • Nov 01Third-quarter earnings released: Revenue beats expectationsThird-quarter revenue exceeded analyst estimates by 14% at CN¥1.69b. Revenue is forecast to grow 26% over the next year, compared to a 41% growth forecast for the Biotechs industry in China.Valuation Update With 7 Day Price Move • Oct 24Market pulls back on stock over the past weekAfter last week's 15% share price decline to CN¥51.27, the stock is trading at a trailing P/E ratio of 72.6x, down from the previous P/E ratio of 85.5x. This compares to an average P/E of 74x in the Biotechs industry in China. Total returns to shareholders over the past three years are 251%.業績と収益の成長予測XSEC:002007 - アナリストの将来予測と過去の財務データ ( )CNY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20285,5001,3938622,279512/31/20275,1301,2005,406789612/31/20264,52093914184233/31/20264,490858676857N/A12/31/20254,595940681878N/A9/30/20254,2679491,1041,050N/A6/30/20254,5251,164861969N/A3/31/20254,4591,1398101,023N/A12/31/20244,3791,0888041,059N/A9/30/20244,9201,3384361,113N/A6/30/20245,4091,395256900N/A3/31/20245,2491,3923461,027N/A12/31/20235,3421,4825921,346N/A9/30/20234,8281,2438071,538N/A6/30/20233,7531,0201,0991,713N/A3/31/20234,7571,1948351,268N/A1/1/20234,5171,076563957N/A9/30/20224,6771,139136662N/A6/30/20225,4971,42554704N/A3/31/20224,4531,2774741,225N/A1/1/20224,4361,2996211,432N/A9/30/20215,3111,7091,0161,642N/A6/30/20214,9251,5599071,594N/A3/31/20214,9691,6217641,495N/A12/31/20205,0231,6137041,325N/A9/30/20204,1341,2846081,166N/A6/30/20203,6841,2889021,295N/A3/31/20203,6821,2719531,271N/A12/31/20193,7001,283N/A1,363N/A9/30/20193,8191,344N/A1,334N/A6/30/20193,4181,194N/A1,451N/A3/31/20193,3511,192N/A1,440N/A12/31/20183,2171,140N/A1,293N/A9/30/20182,738961N/A864N/A6/30/20182,556843N/A590N/A3/31/20182,392773N/A308N/A12/31/20172,368821N/A177N/A9/30/20172,195792N/A146N/A6/30/20172,091801N/A120N/A3/31/20172,061843N/A203N/A12/31/20161,935780N/A330N/A9/30/20161,767737N/A443N/A6/30/20161,671690N/A585N/A3/31/20161,585632N/A549N/A12/31/20151,472589N/A549N/A9/30/20151,386575N/A501N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 002007の予測収益成長率 (年間18.1% ) は 貯蓄率 ( 2.4% ) を上回っています。収益対市場: 002007の収益 ( 18.1% ) CN市場 ( 26.1% ) よりも低い成長が予測されています。高成長収益: 002007の収益は増加すると予測されていますが、大幅には増加しません。収益対市場: 002007の収益 ( 7.8% ) CN市場 ( 16.1% ) よりも低い成長が予測されています。高い収益成長: 002007の収益 ( 7.8% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 002007の 自己資本利益率 は、3年後には低くなると予測されています ( 9.7 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/23 01:29終値2026/07/23 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Hualan Biological Engineering Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。20 アナリスト機関Ethan CuiBofA Global ResearchFusheng CheungChina Galaxy International Securities (Hong Kong)Fang QuanChina International Capital Corporation Limited17 その他のアナリストを表示
お知らせ • Jun 30Hualan Biological Engineering Inc. to Report First Half, 2026 Results on Aug 29, 2026Hualan Biological Engineering Inc. announced that they will report first half, 2026 results on Aug 29, 2026
Declared Dividend • Jun 11Dividend of CN¥0.50 announcedShareholders will receive a dividend of CN¥0.50. Ex-date: 15th June 2026 Payment date: 15th June 2026 Dividend yield will be 7.6%, which is higher than the industry average of 1.6%. Sustainability & Growth Dividend is not covered by earnings (213% earnings payout ratio) nor is it covered by cash flows (270% cash payout ratio). The dividend has increased by an average of 23% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 137% to bring the payout ratio under control. EPS is expected to grow by 65% over the next 3 years, which means the dividend may need to be reduced to reach a sustainable payout ratio.
お知らせ • Jun 10Hualan Biological Engineering Inc. Announces 2025 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 15 June 2026Hualan Biological Engineering Inc. announced 2025 final profit distribution plan to be implemented (A shares) of CNY 5.00000000 per 10 shares(tax included). Record date: 12 June 2026, Ex-date: 15 June 2026, Payment date: 15 June 2026.
Board Change • May 20Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 6 experienced directors. 5 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Zhiqian Zhang was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Mar 31Hualan Biological Engineering Inc. to Report Q1, 2026 Results on Apr 27, 2026Hualan Biological Engineering Inc. announced that they will report Q1, 2026 results on Apr 27, 2026
お知らせ • Mar 28Hualan Biological Engineering Inc., Annual General Meeting, Apr 20, 2026Hualan Biological Engineering Inc., Annual General Meeting, Apr 20, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinxiang, Henan China
お知らせ • Dec 31Hualan Biological Engineering Inc. to Report Fiscal Year 2025 Results on Mar 28, 2026Hualan Biological Engineering Inc. announced that they will report fiscal year 2025 results on Mar 28, 2026
お知らせ • Sep 30Hualan Biological Engineering Inc. to Report Q3, 2025 Results on Oct 30, 2025Hualan Biological Engineering Inc. announced that they will report Q3, 2025 results on Oct 30, 2025
お知らせ • Sep 24Hualan Biological Engineering Inc. Approves Interim Dividend for 2025Hualan Biological Engineering Inc. held its 2nd Extraordinary General Meeting of 2025 on 22 September 2025, approved interim Cash dividend/10 shares (tax included): CNY5.00000000 for 2025.
お知らせ • Aug 29Hualan Biological Engineering Inc. Proposes Interim Cash Dividend for 2025Hualan Biological Engineering Inc. at its EGM to be held on September 22, 2025, proposed the detailed profit distribution plan are as follows: Cash dividend/10 shares (tax included): CNY5.00000000.
お知らせ • Jul 02Hualan Biological Engineering Inc. to Report First Half, 2025 Results on Aug 29, 2025Hualan Biological Engineering Inc. announced that they will report first half, 2025 results on Aug 29, 2025
お知らせ • Apr 01Hualan Biological Engineering Inc. Proposes Final Cash Dividend for the Year 2024Hualan Biological Engineering Inc. announced on 31 March 2025 the profit distribution proposal for the year 2024 as final cash dividend/10 shares (tax included) of CNY 2.00000000.
お知らせ • Mar 31Hualan Biological Engineering Inc. to Report Q1, 2025 Results on Apr 28, 2025Hualan Biological Engineering Inc. announced that they will report Q1, 2025 results on Apr 28, 2025
お知らせ • Mar 29Hualan Biological Engineering Inc., Annual General Meeting, Apr 25, 2025Hualan Biological Engineering Inc., Annual General Meeting, Apr 25, 2025, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinxiang, Henan China
お知らせ • Dec 31Hualan Biological Engineering Inc. to Report Fiscal Year 2024 Results on Mar 29, 2025Hualan Biological Engineering Inc. announced that they will report fiscal year 2024 results on Mar 29, 2025
Reported Earnings • Oct 30Third quarter 2024 earnings released: EPS: CN¥0.27 (vs CN¥0.30 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.27 (down from CN¥0.30 in 3Q 2023). Revenue: CN¥1.84b (down 21% from 3Q 2023). Net income: CN¥483.5m (down 11% from 3Q 2023). Profit margin: 26% (up from 23% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings.
お知らせ • Sep 30Hualan Biological Engineering Inc. to Report Q3, 2024 Results on Oct 31, 2024Hualan Biological Engineering Inc. announced that they will report Q3, 2024 results on Oct 31, 2024
Valuation Update With 7 Day Price Move • Sep 27Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CN¥16.41, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 21x in the Biotechs industry in China. Total loss to shareholders of 39% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥27.89 per share.
Reported Earnings • Aug 30Second quarter 2024 earnings released: EPS: CN¥0.098 (vs CN¥0.096 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.098 (up from CN¥0.096 in 2Q 2023). Revenue: CN¥865.4m (up 23% from 2Q 2023). Net income: CN¥178.4m (up 2.0% from 2Q 2023). Profit margin: 21% (down from 25% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings.
お知らせ • Jun 29Hualan Biological Engineering Inc. to Report First Half, 2024 Results on Aug 30, 2024Hualan Biological Engineering Inc. announced that they will report first half, 2024 results on Aug 30, 2024
Declared Dividend • Jun 08Dividend of CN¥0.30 announcedDividend of CN¥0.30 is the same as last year. Ex-date: 14th June 2024 Payment date: 14th June 2024 Dividend yield will be 1.7%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by earnings (39% earnings payout ratio) but not covered by cash flows (159% cash payout ratio). The dividend has increased by an average of 25% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 62% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Jun 08Hualan Biological Engineering Inc. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 14 June 2024Hualan Biological Engineering Inc. announced final profit distribution plan to be implemented on A shares as cash dividend per ten shares (tax included) of CNY 3.00000000 for the year 2023, payable on 14 June 2024. Record date: 13 June 2024. Ex-date: 14 June 2024.
Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.19 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.14 (down from CN¥0.19 in 1Q 2023). Revenue: CN¥787.3m (down 11% from 1Q 2023). Net income: CN¥261.8m (down 26% from 1Q 2023). Profit margin: 33% (down from 40% in 1Q 2023). Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Apr 01Full year 2023 earnings released: EPS: CN¥0.81 (vs CN¥0.59 in FY 2022)Full year 2023 results: EPS: CN¥0.81 (up from CN¥0.59 in FY 2022). Revenue: CN¥5.34b (up 18% from FY 2022). Net income: CN¥1.48b (up 38% from FY 2022). Profit margin: 28% (up from 24% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.
お知らせ • Mar 30Hualan Biological Engineering Inc. to Report Q1, 2024 Results on Apr 26, 2024Hualan Biological Engineering Inc. announced that they will report Q1, 2024 results on Apr 26, 2024
お知らせ • Dec 30Hualan Biological Engineering Inc. to Report Fiscal Year 2023 Results on Mar 30, 2024Hualan Biological Engineering Inc. announced that they will report fiscal year 2023 results on Mar 30, 2024
Reported Earnings • Nov 01Third quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.17 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.30 (up from CN¥0.17 in 3Q 2022). Revenue: CN¥2.33b (up 86% from 3Q 2022). Net income: CN¥540.6m (up 70% from 3Q 2022). Profit margin: 23% (down from 25% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Aug 24Second quarter 2023 earnings released: EPS: CN¥0.096 (vs CN¥0.19 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.096 (down from CN¥0.19 in 2Q 2022). Revenue: CN¥704.6m (down 59% from 2Q 2022). Net income: CN¥175.0m (down 50% from 2Q 2022). Profit margin: 25% (up from 20% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 29% per year, which means it is performing significantly worse than earnings.
お知らせ • Jun 08Hualan Biological Engineering Inc. Announces Final Dividend on Share A for 2022, Payable on June 14, 2023Hualan Biological Engineering Inc. announced final Cash dividend/10 shares (tax included): CNY 3.00000000 on share A for 2022. Record date: 13 June 2023, Ex-date: 14 June 2023, Payment date: 14 June 2023.
Reported Earnings • Mar 30Full year 2022 earnings released: EPS: CN¥0.59 (vs CN¥0.71 in FY 2021)Full year 2022 results: EPS: CN¥0.59 (down from CN¥0.71 in FY 2021). Revenue: CN¥4.52b (up 1.8% from FY 2021). Net income: CN¥1.08b (down 17% from FY 2021). Profit margin: 24% (down from 29% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Yunlong Wang was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 31Third quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.33 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.17 (down from CN¥0.33 in 3Q 2021). Revenue: CN¥1.25b (down 40% from 3Q 2021). Net income: CN¥317.6m (down 47% from 3Q 2021). Profit margin: 25% (down from 29% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 24Second quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.11 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.19 (up from CN¥0.11 in 2Q 2021). Revenue: CN¥1.71b (up 157% from 2Q 2021). Net income: CN¥349.1m (up 71% from 2Q 2021). Profit margin: 20% (down from 31% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to stay flat compared to a 34% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Jun 21Investor sentiment improved over the past weekAfter last week's 19% share price gain to CN¥22.86, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 30x in the Biotechs industry in China. Total returns to shareholders of 4.1% over the past three years.
Board Change • May 25Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Yunlong Wang was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 01Full year 2021 earnings released: EPS: CN¥0.71 (vs CN¥0.89 in FY 2020)Full year 2021 results: EPS: CN¥0.71 (down from CN¥0.89 in FY 2020). Revenue: CN¥4.44b (down 12% from FY 2020). Net income: CN¥1.30b (down 20% from FY 2020). Profit margin: 29% (down from 32% in FY 2020). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 9.4%, compared to a 51% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Sep 08Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to CN¥30.13, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 36x in the Biotechs industry in China. Total returns to shareholders of 71% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥17.49 per share.
Reported Earnings • Aug 30Second quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.14 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥665.2m (down 6.2% from 2Q 2020). Net income: CN¥204.5m (down 23% from 2Q 2020). Profit margin: 31% (down from 37% in 2Q 2020). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 17% per year whereas the company’s share price has increased by 21% per year.
Reported Earnings • May 02First quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.14 in 1Q 2020)The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: CN¥623.4m (down 8.0% from 1Q 2020). Net income: CN¥252.8m (up 2.2% from 1Q 2020). Profit margin: 41% (up from 37% in 1Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Mar 31Full year 2020 earnings released: EPS CN¥0.89 (vs CN¥0.71 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: CN¥5.02b (up 36% from FY 2019). Net income: CN¥1.61b (up 26% from FY 2019). Profit margin: 32% (down from 35% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Mar 11Full year 2020 earnings released: EPS CN¥0.88 (vs CN¥0.70 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: CN¥5.02b (up 36% from FY 2019). Net income: CN¥1.60b (up 25% from FY 2019). Profit margin: 32% (down from 35% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth.
Analyst Estimate Surprise Post Earnings • Mar 11Revenue beats expectationsRevenue exceeded analyst estimates by 6.3%. Over the next year, revenue is forecast to grow 9.6%, compared to a 61% growth forecast for the Biotechs industry in China.
Valuation Update With 7 Day Price Move • Feb 11Investor sentiment improved over the past weekAfter last week's 17% share price gain to CN¥53.98, the stock is trading at a trailing P/E ratio of 76.7x, up from the previous P/E ratio of 65.5x. This compares to an average P/E of 70x in the Biotechs industry in China. Total returns to shareholders over the past three years are 323%.
Is New 90 Day High Low • Feb 11New 90-day high: CN¥53.98The company is up 21% from its price of CN¥44.63 on 13 November 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥45.10 per share.
Valuation Update With 7 Day Price Move • Jan 12Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥52.97, the stock is trading at a trailing P/E ratio of 75.3x, up from the previous P/E ratio of 64.9x. This compares to an average P/E of 64x in the Biotechs industry in China. Total returns to shareholders over the past three years are 284%.
Valuation Update With 7 Day Price Move • Jan 08Investor sentiment improved over the past weekAfter last week's 19% share price gain to CN¥50.39, the stock is trading at a trailing P/E ratio of 71.6x, up from the previous P/E ratio of 60x. This compares to an average P/E of 65x in the Biotechs industry in China. Total returns to shareholders over the past three years are 261%.
Is New 90 Day High Low • Nov 03New 90-day low: CN¥46.08The company is down 34% from its price of CN¥70.17 on 05 August 2020. The Chinese market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥23.11 per share.
Reported Earnings • Nov 01Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥1.28b, down 4.4% from the prior year. Total revenue was CN¥4.13b over the last 12 months, up 8.3% from the prior year.
Analyst Estimate Surprise Post Earnings • Nov 01Third-quarter earnings released: Revenue beats expectationsThird-quarter revenue exceeded analyst estimates by 14% at CN¥1.69b. Revenue is forecast to grow 26% over the next year, compared to a 41% growth forecast for the Biotechs industry in China.
Valuation Update With 7 Day Price Move • Oct 24Market pulls back on stock over the past weekAfter last week's 15% share price decline to CN¥51.27, the stock is trading at a trailing P/E ratio of 72.6x, down from the previous P/E ratio of 85.5x. This compares to an average P/E of 74x in the Biotechs industry in China. Total returns to shareholders over the past three years are 251%.